MK-677 (Ibutamoren) vs Oxytocin
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
MK-677 (Ibutamoren)Cognitive EnhancementSexual Health & Libido
Oxytocin- Summary
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
- Half-Life
- 24 hours
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- Admin Route
- Oral
- Intranasal, SubQ, IV
- Research
- —
- —
- Typical Dose
- 10–25 mg
- 20–40 IU
- Frequency
- Once daily
- As needed (not daily long-term)
- Key Benefits
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Enhances social bonding and trust
- Reduces social anxiety and fear of rejection
- Improves autism spectrum symptoms (social cognition)
- Reduces cortisol and stress reactivity
- Enhances sexual arousal and intimacy
- Promotes maternal behavior and bonding
- May improve depressive symptoms
- Appetite suppression and metabolic effects
- Side Effects
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Mild uterine cramping (avoid in pregnancy)
- Nasal irritation (intranasal)
- Headache
- Potential emotional over-attachment or jealousy amplification
- +2 more
- Stacks With
- —
- —